Key Takeaways BSX uses AI in diagnostics, imaging, and mapping systems to improve cardiac procedure outcomes. JNJ integrates AI into robotic platforms and digital ecosystems for advanced surgical analytics. GEHC leads in FDA-cleared AI devices and enhances imaging with tools like CleaRecon DL and ABUS Premium.Globally, generative artificial intelligence (Gen AI) and agentic AI are increasingly being integrated into medical devices, transforming both clinical workflows and patient care. Gen AI is primarily ...

Intuitive’s latest advanced energy instrument features a unique curved tip for enhanced precision Vessel Sealer Curved Vessel Sealer Curved, Intuitive’s latest advanced energy instrument SUNNYVALE, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared its latest innovation in advanced energy instrumentation for use wit ...

Led by Dr. Mohit Bhandari, a pioneer in bariatric surgery and President of the Institute of Research Against Digestive Cancer (IRCAD) India, the surgery was remotely performed at a distance of 560 miles and executed on-site at Mohak Bariatric & Robotic Surgery Centre in Indore, India.Two advanced One-Anastomosis Gastric Bypass (OAGB) procedures were performed via telesurgery, with zero perceptible lag, flawless precision, and seamless robotic control using the SSI Mantra 3 system. FORT LAUDERDALE, Fla., Jul ...

MiMedx (MDXG) shares soared 8% in the last trading session to close at $7. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.5% gain over the past four weeks.The sudden rise in price can be attributed to growing investors’ optimism related to the company’s efforts to develop and provide a leading portfolio of products for applications in the wound care, burn and surgical sectors of healthcare.This developer of biomaterials made f ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks with the highest potential to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales to find attractive investment opportunities [3] - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth potential [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of following market trends [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 that also have Style Scores of A or B, while stocks with a 3 (Hold) rank should also possess high Style Scores to ensure potential upside [9][10] Company Spotlight: Universal Health Services (UHS) - Universal Health Services Inc. operates various healthcare facilities and currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of A and a Momentum Style Score of B, indicating potential for growth [11] - Recent analyst revisions have positively impacted UHS's earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising by $0.19 to $19.43 per share, alongside an average earnings surprise of 13.8% [12]

GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to beco ...

Core Insights - Intuitive Surgical (ISRG) received CE-mark approval for its latest surgical robot system, da Vinci 5, which includes over 150 enhancements aimed at improving surgical outcomes and operational efficiency [1][2] - The da Vinci 5 system is cleared for minimally invasive endoscopic procedures across various specialties, expanding Intuitive Surgical's clinical reach in Europe [2][7] - The surgical robots market in Europe is projected to grow from $1.89 billion in 2024 to $3.31 billion by 2030, with a CAGR of 10.3% from 2025 to 2030, driven by technological innovation and increasing chronic conditions [4] Company Developments - The da Vinci 5 system offers 10,000 times more processing power than earlier generations, integrating advanced sensors and software for real-time insights to improve surgeon performance [3] - In Q1 2025, 147 out of 367 da Vinci systems placed globally were da Vinci 5 units, indicating strong demand in the U.S. market [5][7] - The adoption of force feedback instruments in da Vinci 5 procedures has shown significant clinical benefits, including faster recovery times and improved surgical proficiency [5] Market Performance - Intuitive Surgical's performance in Europe remains strong, with 88 earlier versions of da Vinci systems placed in Q1 2025, and over 410,000 procedures performed in 2024 [8] - Despite macroeconomic pressures, the company continues to focus on training and operational optimization to support procedural growth [8][14] - ISRG's stock has gained 18.9% over the past three months, outperforming the industry average of 14.3% [10] Competitive Landscape - Intuitive Surgical faces competition from companies like Medtronic and Stryker, with Medtronic's Hugo system being 20-25% less expensive but noted for a steeper learning curve [9] - Stryker's Hugo leads in orthopedic robotic surgery, indicating a segmented competitive landscape [9] Financial Outlook - The Zacks Consensus Estimate for ISRG's earnings per share has been revised downwards for 2025 and 2026, reflecting rising costs associated with the launch of da Vinci 5 [6] - ISRG is currently trading at a forward price-to-earnings multiple of 64.32X, higher than the industry average of 28.81X, but lower than its five-year median [15] Long-Term Prospects - The CE mark approval for da Vinci 5 opens significant revenue potential in Europe's growing surgical robotics market [15] - Despite near-term challenges, ISRG's dominant market share and focus on innovation position it well for long-term growth [15]

TORONTO, July 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc. (“Novari”), a leading healthcare software provider of patient flow solutions based in Canada. Transaction Details VitalHub has acquired Novari for total up-front consideration of $43.6 million, plus potential performance-based consideration. The purchase price paid at closing was composed of a cash payment of $35.8 ...

Core Insights - The rapid rise of Palantir Technologies in the AI sector may be temporary, with concerns about its high valuation and market sustainability [5][8][7] AI Market Overview - The global addressable market for AI is projected to reach $15.7 trillion by 2030, indicating significant growth potential for various companies [2] Palantir Technologies - Palantir's stock has surged by 1,940% since the beginning of 2023, leading to a market cap exceeding $300 billion [5] - The company has a sustainable competitive advantage with its Gotham and Foundry platforms, which are difficult for competitors to replicate [6] - Palantir's business model includes multiyear government contracts and an enterprise-based subscription model, contributing to predictable cash flow [6] - Despite its strengths, Palantir faces historical challenges that have affected other tech companies, including potential overvaluation and negative investor sentiment [7] - Palantir's price-to-sales (P/S) ratio is currently above 104, significantly higher than the historical range of 30 to 43 for leading companies in similar trends, suggesting an unsustainable valuation [8] Competitors with Growth Potential - Pfizer, with a current market cap of $142 billion, is positioned to grow stronger, especially with its oncology segment bolstered by the acquisition of Seagen [10][13] - PayPal, valued at $73 billion, offers a more attractive risk-reward profile with sustained double-digit growth potential and a forward price-to-earnings ratio of 13 [16][20] - Intuitive Surgical, with a market cap of $193 billion, dominates the robotic-assisted surgical market and is expected to see revenue growth driven by higher-margin services and accessories [21][25]

Core Insights - Intuitive Surgical has received CE mark approval for its da Vinci 5 Surgical System for both adult and pediatric use in Europe, enabling minimally invasive endoscopic procedures [1][3] - The da Vinci 5 is the most advanced multiport robotic-assisted surgical system, featuring over 150 enhancements and building on the design of the da Vinci Xi Surgical System [2][4] - The da Vinci surgical systems have been utilized in over 410,000 procedures in Europe in 2024 and nearly 17 million procedures globally to date [2][7] Company Developments - The da Vinci 5 Surgical System is designed to improve surgical outcomes, efficiency, and provide actionable insights for healthcare systems [4][8] - Intuitive has been developing robotic-assisted technology for 30 years, with nearly 90,000 surgeons trained worldwide [7] - The da Vinci 5 system offers enhanced surgical capabilities, including advanced 3D vision, ergonomic design, and operational efficiencies [8][10] Market Impact - The introduction of the da Vinci 5 provides surgeons in Europe with greater choice and flexibility, supporting quality care for more patients [5][6] - The system aims to address critical challenges faced by healthcare systems across Europe, potentially transforming surgical practices [4][5]